Streetbeat News

Earnings

RY

Royal Bank of Canada (NYSE:RY) is scheduled to release its quarterly earnings report on February 28, 2024, with analysts expecting an EPS of $2.08. The company's past earnings performance shows a pattern of beating EPS estimates, which has occasionally led to positive stock price movements the following day. Shares are currently trading at $97.97, having decreased by 0.37% over the last year. Investors are looking for not only an earnings beat but also positive guidance for future growth.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 2:01 pm

HPQ

HP Inc. (NYSE:HPQ) is scheduled to release its quarterly earnings report on February 28, 2024. Analysts predict an EPS of $0.81. Investors are keen on both the earnings outcome and the company's guidance for future growth. HP's stock performance has been slightly negative over the past year, with a 0.1% decrease. Historical data shows mixed reactions to past earnings, with the stock price fluctuating based on earnings performance and guidance.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 2:00 pm

SWTX

SpringWorks Therapeutics (NASDAQ:SWTX) reported Q4 earnings with an EPS of $-1.45, missing estimates by -17.0%. Revenue increased by $5.45 million from the previous year. Despite beating EPS estimates last quarter, the share price dropped by 4.0% the following day.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 2:00 pm

DNLI

Denali Therapeutics (NASDAQ:DNLI) reported Q4 earnings with an EPS of $-0.86, missing estimates by -7%, and a revenue decrease of $10.28M from the previous year. This follows a pattern of mixed past earnings performances, including a notable beat in Q2 2023 but a subsequent 5% share price drop.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 2:00 pm

JPM

QCOM

STLD

URNM

On CNBC's 'Halftime Report Final Trades,' analysts recommended North Shore Global Uranium Mining ETF (URNM), JPMorgan Chase & Co. (JPM), Steel Dynamics, Inc. (STLD), and Qualcomm Inc. (QCOM) based on various factors including market trends, company performance, and economic forecasts. JPMorgan's CEO Jamie Dimon expressed concerns about a potential U.S. economic recession, while Steel Dynamics announced a dividend increase, and Qualcomm reported a revenue beat.

Portfolio Pulse from Avi Kapoor

February 27, 2024 | 1:58 pm

ACRS

Aclaris Therapeutics (NASDAQ:ACRS) reported Q4 earnings, beating estimates with an EPS of $-0.3 against an expected $-0.34. Revenue increased by $9.82 million from the previous year. Despite beating EPS estimates in the past, such performance has previously led to a 1.0% drop in share price the following day.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:55 pm

ARVN

Arvinas (NASDAQ:ARVN) reported Q4 earnings with a significant miss, posting an EPS of $-2.53 against an estimate of $-1.28, marking a -98.0% deviation. Revenue also saw a substantial decrease, down $81.10 million from the previous year. This follows a pattern of fluctuating performance in past quarters, with the last quarter showing a beat on EPS estimates but a subsequent 7% drop in share price.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:50 pm

VERV

Verve Therapeutics (NASDAQ:VERV) reported Q4 earnings, beating estimates with an EPS of $-0.69 against an expected $-0.82 and saw a revenue increase of $4.13 million year-over-year. Despite beating last quarter's EPS estimate, the share price dropped by 10% the following day.

Portfolio Pulse from Benzinga Insights

February 27, 2024 | 1:50 pm

LOW

Lowe's Companies Inc (NYSE:LOW) reported Q4 FY23 sales of $18.60 billion, slightly above estimates but saw a 6.2% Y/Y decrease in comparable sales due to weak DIY demand and unfavorable weather. Despite this, EPS of $1.77 beat estimates. Gross profit and operating income fell, but margins improved. The company issued a weak FY24 outlook with expected revenue and EPS below consensus estimates, leading to a 1.22% premarket drop in LOW shares.

Portfolio Pulse from Lekha Gupta

February 27, 2024 | 1:46 pm

HIMS

JANX

PUBM

Shares of Janux Therapeutics (JANX), PubMatic (PUBM), and Hims & Hers Health (HIMS) surged following positive updates. JANX soared 156% after announcing promising clinical data. PUBM jumped 38% on strong Q4 results and future guidance. HIMS increased 22% also due to favorable Q4 outcomes and guidance.

Portfolio Pulse from ryanfaloona@benzinga.com

February 27, 2024 | 1:44 pm